Shire Pharmaceuticals Group plc

Shire is an international specialty pharmaceutical company with a strategic focus on four therapeutic areas: central nervous system disorders, metabolic diseases, oncology and gastroenterology. The group has a sales and marketing infrastructure with a broad portfolio of products targeting with its own sales force the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain, with plans to add Japan by 2004. Shire intends to cover other significant pharmaceutical markets indirectly through distributors. We have already appointed distributors. Shire’s global search and development expertise has to date successfully provided eight marketed products, of which Reminyl for the treatment of Alzheimer’s disease is the latest to be launched in its first market, the UK. The current pipeline of 15 projects includes Reminyl in registration in the US and various other markets and 9 others that are post Phase II. Shire is actively seeking to acquire further marketed products and development projects to enhance the potential for future growth.

Activity:

- Manufacturing
- Market Research & Marketing

Product / Technology type(s) covered:

- Pharmaceuticals / Therapeutics
- Prescription drugs (Rx)

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active: Europe , North America

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: